Ruth Tal-Singer is VP, Medicine Development Leader, in GSK’s Respiratory R&D, leading a multidisciplinary international matrix team accountable for transforming clinical development through strategic partnerships that drive quality in respiratory clinical trials through improved disease understanding and application of the digital ecosystem. Recognised as an innovator and a leader in pre-competitive partnerships between pharma, patients, academia and governments: Industry Chair of the COPD Foundation Biomarker Qualification Consortium, Co-Chair of the ECLIPSE Steering Committee, co-PI of the UK ERICA Consortium, and member of the COPDGene Scientific Advisory Board, and COPDMAP management board. Ruth is a clinical scientist with a PhD in molecular virology from the University of Pennsylvania, Philadelphia, USA and over 20 years of R&D experience at GSK in roles of increasing responsibility. She developed and optimised models and technologies used to test antiinflammatory agents and bronchodilators in Phase I-IV trials. Currently the Medicine Development Leader for a Late Stage Project in COPD. Authored over 140 peer-reviewed highly cited scientific publications. Ruth is a GSK Senior Fellow: the GSK Fellows Program provides a clear vision of what technical scientific ‘excellence’ looks like. Fellows have high visibility and form strong relationships and credibility both internally and with the external scientific community.